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Background: In fructose 1,6 bisphosphatase (FBPase) deficiency, management aims to prevent hypoglycaemia and
lactic acidosis by avoiding prolonged fasting, particularly during febrile illness. Although the need for an emergency
regimen to avoid metabolic decompensation is well established at times of illness, there is uncertainty about the
need for other dietary management strategies such as sucrose or fructose restriction. We assessed international
differences in the dietary management of FBPase deficiency.
Methods: A cross-sectional questionnaire (13 questions) was emailed to all members of the Society for the Study
of Inborn Errors of Metabolism (SSIEM) and a wide database of inherited metabolic disorder dietitians.
Results: Thirty-six centres reported the dietary prescriptions of 126 patients with FBPase deficiency. Patients’ age at
questionnaire completion was: 1-10y, 46% (n = 58), 11-16y, 21% (n = 27), and >16y, 33% (n = 41). Diagnostic age
was: <1y, 36% (n = 46); 1-10y, 59% (n = 74); 11-16y, 3% (n = 4); and >16y, 2% (n = 2). Seventy-five per cent of centres
advocated dietary restrictions. This included restriction of: high sucrose foods only (n = 7 centres, 19%); fruit and
sugary foods (n = 4, 11%); fruit, vegetables and sugary foods (n = 13, 36%). Twenty-five per cent of centres (n = 9),
advised no dietary restrictions when patients were well. A higher percentage of patients aged >16y rather than
≤16y were prescribed dietary restrictions: patients aged 1-10y, 67% (n = 39/58), 11-16y, 63% (n = 17/27) and >16y,
85% (n = 35/41). Patients classified as having a normal fasting tolerance increased with age from 30% in 1-10y, to
36% in 11-16y, and 58% in >16y, but it was unclear if fasting tolerance was biochemically proven. Twenty centres
(56%) routinely prescribed uncooked cornstarch (UCCS) to limit overnight fasting in 47 patients regardless of their
actual fasting tolerance (37%). All centres advocated an emergency regimen mainly based on glucose polymer for
illness management.
Conclusions: Although all patients were prescribed an emergency regimen for illness, use of sucrose and fructose
restricted diets with UCCS supplementation varied widely. Restrictions did not relax with age. International
guidelines are necessary to help direct future dietary management of FBPase deficiency.
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Fructose 1, 6 bisphosphatase (FBPase) deficiency (OMIM
#229700), is a rare, autosomal recessive inherited disorder
of gluconeogenesis [1]. It was first described by Baker and
Winegrad in 1970 [2], who found recurrent episodes of
hypoglycaemia and lactic acidosis in a 5-year-old girl; her
elder brother died at the age of 6 months following severe
metabolic acidosis probably with the same condition [2].
FBPase is a key gluconeogenic enzyme that irreversibly
catalyses the hydrolysis of fructose-1,6-biphosphate to
fructose-6-phosphate and inorganic phosphate [3]. Its in-
activity prevents the endogenous formation of glucose
from precursors including lactate, glycerol, fructose, and
gluconeogenic amino acids such as alanine [4]. Conse-
quently alanine, lactate, glycerol, glycerol-3-phosphate and
ketones [5] accumulate during fasting. Hypoglycaemia
occurs after prolonged fasting when glycogen stores are
depleted [3]. FBPase incidence is unknown, but is possibly
between 1: 350,000 and <1: 900,000 in Europe [1, 6]. Cases
have also been identified in Japan [3], China, USA [7],
Israel [8], Turkey [9], Morocco, and Saudi Arabia [10].
Incidence is higher in countries with greater rates of
consanguinity [11].
Clinical presentation may be as early as 1-4 days of
life, when glycogen stores are limited, and is associated
with a high mortality [6], but many children experience
recurrent acute episodes before diagnosis is made [4].
Symptoms include hypoglycaemia, metabolic acidosis,
lactic acidosis, ketonuria, apnoea, seizures, severe
hyperventilation, hypotonia, and moderate hepatomegaly
[12, 13], usually accompanying prolonged fasting associ-
ated with illness [14].
Dietary management is not well characterised.
Management aims to prevent hypoglycemia and lactic
acidosis by avoiding prolonged fasting and excessive in-
take of fructose and sucrose, particularly in young
children. Although fructose is a gluconeogenic precur-
sor, the severity or need for sucrose and fructose restric-
tion remains indeterminate. It is often reported that
fasting should not exceed 8 h, but it is accepted that
fasting tolerance improves with age [2, 15]. It is unclear
if dietary strategies such as the use of uncooked
cornstarch (UCCS) to limit overnight fasting is necessary
or even effective. Treatment of metabolic decompensa-
tion with oral or intravenous glucose ± sodium
bicarbonate is essential. Between episodes of acute
metabolic decompensation, patients usually remain well
and it is considered a benign condition once diagnosis
and management is established [4, 16].
Due to the rarity of the disorder, few metabolic centres
manage more than 10 patients. In order to try and
understand long-term dietary prescriptions in FBPase
deficiency, we have identified the differences in dietary
management of a large international patient cohort.Methods
A cross sectional questionnaire (power point document)
was sent to all members of the Society for the Study of
Inborn Errors of Metabolism (SSIEM) by email as well as
an extensive database of IMD dietetic colleagues (n = 250)
who have collaborated on previous surveys [17, 18].
The questionnaire was comprised of 13 open and
multiple-choice questions about dietary practices in
FBPase deficiency. Information on: number of patients,
ethnicity, age at diagnosis, dietary restrictions, UCCS,
fasting tolerance and emergency regimens was collected.
Questionnaire responses were divided by geographical
region in order to analyse for any effect on dietary prac-
tices. Ethical consent was not sought as outcome data
and patient identifiable data was not obtained. Data was
analysed using descriptive statistics only.
Results
Participants
Thirty-six international IMD centres from 15 countries
returned questionnaires, reporting 126 patients with
FBPase deficiency. The majority of responses were from
dietitians (92%, n = 36) with a minority from physicians
(8%, n = 3). Forty-five patients were Caucasian, 38 Arabic
and 27 Asian (23 Pakistani and 4 Bangladeshi). The
remaining 16 patients belonged to other ethnicities that
were not identified. There was a median of 2 (1-24)
patients per centre.
The centres were divided into the following geograph-
ical regions: Western Europe: 9 centres caring for n = 18
patients (Austria [n = 1], France [n = 6], Germany [n = 2]
and The Netherlands [n = 9]); Southern Europe: 9 centres
caring for n = 35 patients (Greece [n = 8], Italy [n = 13],
Spain [n = 1] and Turkey [n = 13]); Northern Europe: 12
centres caring for n = 41 patients (Sweden [n = 3] and
United Kingdom [n = 38]), and non-Europe: 6 centres car-
ing for n = 32 patients (Iran [n = 3], Saudi Arabia [n = 25],
Brazil [n = 2], United States of America [n = 1] and New
Zealand [n = 1]).
Patient’s age at diagnosis was: < 1y, 36% (n = 46); 1-10y,
59% (n = 74), 11-16y, 3% (n = 4), and >16, 2% (n = 2).
Patients were diagnosed in adulthood in Brazil and USA.
Data was not collected on age of first clinical symptoms
although several centres commented there was a delay
between age of presentation and diagnostic age. At the
time of questionnaire completion, patient age was
categorised into the following groups: 46% (n = 58) 1-10y,
21% (n = 27) 11-16y; and 33% (n = 41) >16y.
Dietary restrictions when well (Table 1)
Most patients in 75% of centres (n = 27/36) were pre-
scribed sucrose or fructose restrictions; 7 centres re-
stricted high sucrose foods only (n = 17 patients), 4
centres (30 patients) restricted sugary foods and fruits
Table 1 Number of patients prescribed each dietary restriction by geographical region
Geographical region
(Number of centres)
Patient number (n)
No dietary restriction Sugary foods, fruit and
vegetables restriction
Sugary foods and
fruit restriction
Only sugary foods
restriction
Western Europe (n = 18) 3 9 5 1
Southern Europe (n = 35) 3 19 0 13
Northern Europe (n = 41) 28 11 1 1
Non-Europe (n = 32) 1 5 24 2
Totals (n = 126) 35 44 30 17
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vegetables and sugary foods. In 3 centres (9 patients),
dietary prescription varied according to clinical signs
and symptoms. Three centres from Western Europe,
Northern Europe and Non-Europe calculated fructose
amounts. More adults than children were prescribed
dietary restrictions (age 1-10y, 67% [n = 39/58], 11-16y,
63% [n = 17/27] and >16y, 85% [n = 35/41]).
Twenty-five percent of centres (n = 9, 35 patients) did
not advocate any dietary restrictions when well.
Nineteen patients were aged 1-10y, 10 aged 11-16y and
6 patients aged >16y. Dietary restrictions by geographical
region are shown in Table 1. One patient was tube fed
due to comorbidities.
Fasting tolerance and use of uncooked cornstarch
Professionals reported fasting tolerance in 112 (89%)
patients, but it was unclear on what criteria this was
established. Fasting tolerance improved with age, with
the number of patients with reported normal fasting
tolerance in each age group increasing from 30% (n =
14/47) in 1-10y, to 36% (n = 9/25) in 11-16y and 58%
(n = 23/40) in >16y. Twenty (56%) centres (Table 2)
routinely prescribed UCCS to extend overnight fasting,
which represented 37% (n = 47/126) of all patients; but
still most patients (n = 79) were managed without UCCS
prescription. In the 47 patients prescribed UCCS, the
mean dose (g/kg/dose) for the group was 1.1 and by age
category was aged 1-10y (n = 30), 1.2; 11-16y (n = 7); 1.3;
>16y (n = 10), 1.0. Figure 1 shows the mean amount ofTable 2 Number of centres prescribing uncooked cornstarch by
geographical region
Geographical region
(Number of centres)
Number of centres (n)
Number of centres
prescribing uncooked
cornstarch
Number of centres
not prescribing
uncooked cornstarch
Western Europe (n = 9) 4 5
Southern Europe (n = 9) 8 1
Northern Europe (n = 12) 5 7
Non-Europe (n = 6) 3 3
Totals (n = 36) 20 16UCCS dose given in each age range in centres from dif-
ferent geographical regions. Two centres prescribed Gly-
cosade (Vitaflo®), a slow release starch. Other complex
carbohydrates such as cereals, bread, rice or pasta were
encouraged as alternatives to UCCS before bedtime.
Sixteen centres (n = 53 patients) did not use UCCS be-
fore overnight fasting (7 centres from Northern Europe,
5 centres from Western Europe, 3 non-European centres
[including 24 patients from one centre] and 1 centre
from Southern Europe). In patients prescribed UCCS
(data available in 36 out of 47 patients), 36% (n = 13) of
centres reported a fasting tolerance <10 h and 64% (n =
23) a fasting tolerance >10 h when well. When fasting
tolerance was <10 h, the median amount of UCCS given
prior to fasting was 1 g/kg (n = 13 patients); the same
amount of UCCS was given when fasting tolerance was
≥10 h (n = 23 patients). Figure 2 shows the mean dose of
UCCS given when fasting is <10 h and >10 h per patient.
We did not collect biochemical evidence of fasting toler-
ance, so it was unclear how respondents determined this
or when it was last estimated in individual patients.
Dietary management when unwell
All centres prescribed an emergency regimen using glu-
cose polymer during illness. The median % glucose con-
centration from glucose polymer used in emergency
feeds during illness was 10% (10-15%) for infants aged 0-
12 months; 15% (10-23%) for children aged 1-2y; 20%
(10-25%) for children aged 3-10y and 25% (10-30%) in
patients over >10y. Only 2 centres used fructose sources
such as fruit juice or fruit squash to flavour glucose
polymer when glucose polymer was refused. Extra glu-
cose polymer was used in the recovery period in 21 out
of 36 centres (58%). Twenty-seven centres (75%) re-
ported that patients accepted oral glucose polymer for
their emergency regimen. When it was refused, admis-
sion to hospital for IV fluids was advocated.
Discussion
This is the first paper reporting the dietary management
of 126 patients with FBPase deficiency from 36 inter-
national centres. With the exception of emergency regi-
mens based on glucose polymer, dietary treatment was
Fig. 1 Mean amount of uncooked corn-starch (g/kg) prescribed per
dose by each centre from different geographical regions in each
age range
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fructose and without any relaxation with increasing age.
The use of UCCS pre-overnight fast was also not stand-
ard practice, although when it was used, a similar
amount was prescribed per kg body weight regardless of
age and fasting tolerance.
Although it is commonly documented that younger
patients have reduced tolerance to fructose, sucrose and
sorbitol [4, 15], the necessity for dietary restriction is less
clear with age. There is an early case report of an 8 year
old who had an acute episode associated with a fructose
sweetened cough syrup [19]. Unexpectedly in our survey
most patients were prescribed a fructose/sucrose restric-
tion when patients were well. Steinman suggests that pa-
tients usually tolerate sweet foods (up to 2 g fructose/kg
body weight per day) when given evenly distributed over
the day [4], and stringent restriction of fructose intake is
unnecessary [4]. Large amounts of fructose especially
after a fasting period may lead to metabolic decompen-
sation [20]. It is important to investigate if there are
more episodes of metabolic decompensation between
patients on or off maintenance dietary restrictions.
It is clear in infancy and young children that fasting
times are limited and infants commonly develop clinical
symptoms following withdrawal of night feeding: oneFig. 2 Mean dose of uncooked corn-starch (g/kg) prescribed per
dose for each patient when fasting time is below and above 10 hchild died at 3 days of age [1], one developed physical
and developmental problems at 3y of age [21] and there
are case reports of unexplained hypoglycaemia that
stopped at 10y of age [13], but in most cases overall out-
come is good. Researchers have previously suggested that
fasting tolerance increases with age [2, 15]. Moses et al.
[8] suggested that fasting when well is similar to the gen-
eral population, explained by an increased capacity to
store glycogen in the liver, resulting in less dependency of
the maintenance of blood glucose on gluconeogenesis.
However, symptoms reported in adulthood have been
associated with a combination of illness and fasting during
Ramadan [22], pregnancy [23], alcohol consumption [24],
weight loss, and extensive exercise training (the latter re-
quires careful management) [13].
In 1990, the use of UCCS was reported for the first time
by Burlina et al. [25] for 3 cases with FBPase deficiency.
They gave 2 g/kg at midnight to prevent hypoglycaemia
and since then it has become routine practice in some
centres. Although 56% of centres reported its use, a previ-
ous UK survey found only 17% of patients were given
UCCS [26]. The mean amount of UCCS given in our sur-
vey was lower than the dose used by Burlina et al. [25] but
there is no efficacy data to support its use or dosage in
FBPase deficiency. UCCS has limited benefit when fasting
is extended to over 10 h. In our survey, there were no dif-
ferences in the amounts prescribed for patients with a
fasting tolerance over or below 10 h. Glycosade (Vitaflo®)
a slow release starch was used by 2 centres, and although
it has been shown to be effective in preventing
hypoglycemia in patients with glycogen storage disease
(GSD) types Ia and Ib [27], its efficacy has not been re-
ported in non-GSD conditions.
There are some limitations in this study. This data was
cross-sectional rather than prospective. Data was col-
lected regarding dietary prescription rather than actual
patient’s intake and we have no information about
patient adherence with daily restrictions. Data on out-
come was not collected therefore we were unable to as-
sess if patients on fructose and sucrose restriction had
fewer episodes of hypoglycaemia and lactic acidosis
which were not associated with illness. No biochemical
data was collected on fasting studies to support fasting
times and it was unclear how health professionals estab-
lished fasting times. Most centres only cared for small
patient numbers [median n = 2 (1-24)].
Conclusion
This study describes the dietary prescription from re-
sponses given to an international questionnaire for one
of the largest cohort of patients with FBPase deficiency.
This will provide groundwork information to help health
professionals when standardising dietary care. Although,
the use of an emergency regimen was universal, sucrose
Pinto et al. Orphanet Journal of Rare Diseases  (2018) 13:21 Page 5 of 6and fructose dietary restrictions and the use of UCCS
varied widely and particularly in older patients it may be
unnecessary. International guidelines on management
would optimise dietary treatment preventing any un-
necessary over restriction and risk of nutritional defi-
ciencies but also maintaining patient’s safety, which is
the primary objective.
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